Opill
(norgestrel)Phase 3Small molecule
Opill is one of 80 small molecule programs targeting Contraception. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
79
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
258 competitors in Endometrial Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
Femara
NovartisPhase 3
Paraplatin
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Adriamycin
PfizerPhase 3
Lynparza
AstraZenecaPhase 3
Lenvima
EisaiPhase 3
Tecentriq
RochePhase 3
Trodelvy
GileadPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ovarian1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
OPILL
NDA NDA017031
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for norgestrel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details